Advocacy

Biosimilars have the potential to improve the quality of life for patients while at the same time saving the health system billions of dollars each year.

Over 10 years of the Generic and Biosimilar programs at FDA, the generic and biosimilar industry has provided more than $4 billion for review and approval of lower-cost treatments for America’s patients. The result is more than $2 trillion in savings to patients – including $469 billion from new generics and more than $12 billion from biosimilars – and a dramatic increase in patient access to life-saving treatments.

AAM opposes abuses of the patent system by brand-name drug companies, and we advocate for patent reform that lends itself to timely patient access to safe, effective and more-affordable medicines for patients in the United States.

Unless it is repealed, the Medicaid Generics Penalty could destabilize the robust market for generic drugs and impede patient access to affordable, lifesaving drugs.

AAM works with federal and state level governments to promote best practices aimed at increasing the use of generic medicines and saving taxpayer money. These efforts include rapid responses to anti-substitution stories, advocating for specific generic substitution laws and general education.

AAM promotes and protects access to affordable medicines in trade agreements and represents these interests before the U.S. Trade Representative, the Department of Commerce, Congress, The White House and other stakeholders.